S&P 500 Consumer Staples Sector SEC Filings — March 30, 2026

30-03-2026

Neumora Therapeutics reported Q4 and FY 2025 financial results with reduced R&D expenses (Q4 $44.7M vs $45.9M prior year; FY $176.1M vs $200.9M, down ~12%) and G&A expenses (Q4 $13.8M vs $17.0M; FY $60.1M vs $62.5M), alongside pipeline progress including full enrollment of KOASTAL-2 and -3 trials (topline Q2 2026), promising NMRA-511 Phase 1b data in AD agitation, NMRA-898 selected for schizophrenia, and NMRA-215 DIO study support despite toxicology delay. However, cash decreased to $182.5M from $307.6M, net loss slightly increased in Q4 to $59.4M from $58.8M while improving FY to $236.9M from $243.8M, with runway into Q3 2027. A 13-week rat toxicology study for NMRA-215 showed unexpected non-dose-dependent findings, prompting a repeat study and clinic initiation delay to Q1 2027.

• ·NMRA-511 plans: MAD expansion cohort data H2 2026, Phase 2 initiation Q1 2027.
• ·NMRA-898: ~80-100 hour half-life, dose-proportional exposures, MAD study data H2 2026.
• ·NMRA-215 toxicology: NOAEL in 28-day rat/dog and 13-week dog studies; repeat 13-week rat study due to non-dose-dependent findings in 5/142 animals.

30-03-2026

Aptera Motors Corp reported a Q4 2025 GAAP net loss of $15.5 million, up from $8.9 million YoY, and full-year GAAP net loss of $43.9 million, up from $34.9 million YoY, driven by higher operating expenses of $15.1 million in Q4 and $48.1 million for the year. Adjusted non-GAAP net loss improved for the full year to $18.5 million from $20.1 million, supported by $4.2 million in other income primarily from a California Energy Commission grant, though cash and equivalents declined to $9.6 million from $13.2 million at year-end. Post-period, the company raised $17.1 million in Q1 2026 to support validation assembly and production goals.

• ·Q4 GAAP net loss per share: $(0.57) vs $(0.38) prior year
• ·FY GAAP net loss per share: $(1.79) vs $(1.52) prior year
• ·Public company transition costs: $717K in Q4 2025 and $1.1M FY 2025
• ·Stock-based compensation: $6.1M Q4 2025 ($4.5M G&A, $1.5M R&D); $24.3M FY 2025
• ·Follow-on public offering: $9.0M on Jan 26, 2026; warrant exercises $8.1M including $6.3M inducement on Mar 12, 2026
• ·Carlsbad facility lease extended through March 31, 2028

30-03-2026

ARKO Petroleum Corp. reported Q4 2025 net income of $8.1 million, up from $7.5 million YoY, and full-year net income of $32.7 million, down from $40.2 million, while Adjusted EBITDA increased to $36.9 million in Q4 (vs. $35.4 million) and $143.5 million for the year (vs. $139.2 million). However, net cash provided by operating activities declined sharply to $16.4 million in Q4 (vs. $35.1 million) and $79.6 million for the year (vs. $106.8 million), and segments showed mixed results with wholesale gains offset by declines in comparable sites due to macroeconomic pressures, flat-to-down volumes in Fleet Fueling, and GPMP fuel contribution down due to fewer related-party gallons. Post-period, the company completed its IPO, applying $206.7 million in net proceeds to reduce net debt to a pro forma $319.9 million, and declared a $0.26 per share quarterly dividend.

• ·Wholesale fuel gallons sold at fuel supply locations: 211,406 (Q4 2025) vs. 201,317 (Q4 2024); consignment: 37,204 vs. 38,563 (slight decline).
• ·Fleet Fueling proprietary cardlock gallons: 31,420 (Q4 2025) vs. 32,888 (decline); FY 129,459 vs. 136,104 (decline).
• ·GPMP related party sites: 1,095 at Dec 31, 2025 vs. 1,356 at Dec 31, 2024.
• ·Maintenance capex FY 2025: $6.9M; growth capex: $20.6M.
• ·Total liquidity as of Dec 31, 2025: $434.3M.

30-03-2026

For the year ended December 31, 2025, ImmuCell Corp reported product sales growth of 4% YoY to $27,644,174, driven by a 13% decline in costs of goods sold, resulting in gross profit surging 44% to $11,445,203 and net operating income turning positive at $1,649,305 from a prior loss. However, administrative expenses increased 44%, other expenses net rose 429% to $2,677,762, and a $2,667,100 impairment charge on property, plant, and equipment was recognized after pausing investment in Re-Tain® manufacturing to focus on First Defense®, contributing to a narrowed net loss of $1,040,027 (52% improvement) while total assets declined 6% to $42,532,447.

• ·Net cash provided by operating activities increased to $2,475,292 in 2025 from $357,903 in 2024.
• ·Net cash used for investing activities was $1,214,307 in 2025 vs $461,225 in 2024.
• ·Inventory increased to $9,267,369 as of Dec 31 2025 from $7,112,623.
• ·Property, plant and equipment net decreased to $21,074,694 as of Dec 31 2025 from $25,349,019.
• ·Critical audit matters include valuation of inventory and impairment of PPE related to Re-Tain® assets.
• ·Leased properties total approx. 29,700 sq ft (175A and 175B Industrial Way) for milling, filling, warehouse.

30-03-2026

Accelerant Holdings, an emerging growth company under the JOBS Act, has issued its proxy statement for the hybrid 2026 Annual General Meeting on May 12, 2026, at 10:00 a.m. BST in London or via webcast, with pre-registration required at https://web.viewproxy.com/arx/2026. Shareholders of record as of March 13, 2026, will vote on electing three Class I directors for three-year terms expiring in 2029 and ratifying PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026. As of the record date, 222,160,004 common shares are outstanding, comprising 116,757,858 Class A shares (1 vote each) and 105,402,146 Class B shares (10 votes each), with a simple majority quorum required.

• ·Quorum requires holders of a simple majority of common shares present in person or by proxy.
• ·Proxy deadlines: mail by May 11, 2026; internet at www.AALvote.com/ARX by 11:59 p.m. ET on May 11, 2026.
• ·Election of directors requires simple majority of votes cast; ratification of PwC requires majority of votes cast at meeting with quorum.
• ·No cumulative voting in director elections; abstentions and broker non-votes do not impact proposals.

30-03-2026

Osisko Development Corp. filed its Form 40-F Annual Report on March 30, 2026. The filing lists the company's Common Shares (no par value, trading symbol ODV) registered on the New York Stock Exchange and Warrants (exercisable for one Common Share at $10.70, trading symbol ODVWZ) on The Nasdaq Stock Market LLC.

30-03-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on March 30, 2026, under Item 8.01 to furnish a press release titled 'AITX's RAD Reports Its Strongest ISC West Showing to Date,' attached as Exhibit 99.1. The filing notes that the information is furnished and not deemed filed for liability purposes. No financial metrics or period comparisons are disclosed.

• ·Filing Type: 8-K (Items 8.01, 9.01)
• ·Date of Report: March 30, 2026
• ·Registrant State: Nevada; CIK: 0001498148; EIN: 27-2343603
• ·Principal Address: 10800 Galaxie Avenue, Ferndale, Michigan 48220

30-03-2026

Aldabra 4 Liquidity Opportunity Vehicle, Inc. (ALOV), a blank check company incepted on July 24, 2025, reported total assets of $285,064, including $23,583 in cash and $261,481 in deferred offering costs, as of December 31, 2025. Total liabilities stood at $338,146, resulting in a shareholder’s deficit of $53,082, with a net loss of $78,082 for the period from inception through December 31, 2025, driven entirely by formation and general administrative expenses and no revenue.

• ·Accounts payable: $11,246 as of December 31, 2025
• ·Accrued expenses: $13,125 as of December 31, 2025
• ·Accrued offering costs: $113,775 as of December 31, 2025
• ·Basic and diluted net loss per Class B ordinary share: ($0.01)
• ·Class B ordinary shares authorized: 20,000,000

30-03-2026

Remora Capital Corp's 10-K annual report filing highlights its pursuit of regulated investment company (RIC) status under subchapter M of the Internal Revenue Code and business development company (BDC) status under the 1940 Act, including asset composition requirements such as at least 50% in cash equivalents and limited issuer exposures. It references small company thresholds of total assets not exceeding $4 million and capital/surplus of at least $2 million, alongside a gross revenue trigger of $1.235 billion. Risks disclosed include corporate debt market declines reducing portfolio NAV, global economic uncertainties affecting operations, and mandatory debt prepayments limiting portfolio company flexibility.

• ·RIC asset test limits: other securities of any one issuer not more than 5% of assets or 10% of voting securities.
• ·Risk of increased net unrealized depreciation from price declines and illiquidity in corporate debt markets.

30-03-2026

On March 23, 2026, Oncotelic Therapeutics, Inc. announced that Sapu Nano, in which the Company holds a minority interest, will present new data on evorlimus toxicology at the Society of Toxicology (SOT) 2026 Annual Meeting and ToxExpo in San Diego, California. The press release is attached as Exhibit 99.1 and the poster presentation as Exhibit 99.3. No financial impacts or performance metrics were disclosed.

• ·Event reported date: March 23, 2026
• ·Filing signed: March 27, 2026
• ·Location: San Diego, California

30-03-2026

SmartStop Self Storage REIT, Inc. filed an 8-K on March 30, 2026, under Items 7.01 and 9.01, furnishing investor presentation materials as Exhibit 99.1 for use in investor communications pursuant to Regulation FD. The materials are deemed furnished and not filed, avoiding liabilities under Section 18 of the Exchange Act. The report was signed by James R. Barry, Chief Financial Officer and Treasurer.

• ·Securities: Common Stock, $0.001 par value, trading symbol SMA on New York Stock Exchange
• ·Principal executive offices: 10 Terrace Road, Ladera Ranch, California 92694
• ·Telephone: (866) 418-5144

30-03-2026

Electra Battery Materials Corp's 20-F Annual Report for the year ended December 31, 2025, shows significant improvements in liquidity risk, with short-term liabilities (<1 year) decreasing 44% to $6,623 from $11,797 in 2024, primarily due to the absence of convertible notes payable. Medium-term (1-2 years) liabilities dropped over 99% to $79 from $9,755, and long-term (>2 years) liabilities declined 59% to $44,045 from $107,633. Foreign currency net USD exposure also improved markedly, reducing to -$16,128 CAD from -$65,132 CAD, driven by higher cash balances and lower debt.

• ·2025 short-term liabilities include accounts payable and accrued liabilities of $5,817 and deferred government grant of $642.
• ·Convertible notes payable of $8,057 (<1 year), $8,012 (1-2 years), and $99,071 (>2 years) present in 2024 liquidity table but absent in 2025.
• ·2025 USD-denominated cash and cash equivalents rose to $25,019 (CAD) from $3,391 (CAD) in 2024.

30-03-2026

On March 30, 2026, KEEMO Fashion Group Limited experienced a change in control when Addentax Group Corp. acquired 34,200,000 shares of common stock, representing approximately 62.18% of the voting power on a fully diluted basis, from Guang Wen Global Group Limited. The transaction, pursuant to a Stock Purchase Agreement dated February 17, 2026, was completed for approximately $5.5 million, satisfied through the transfer of a portion of an existing bond held by the Company. No other financial performance metrics or operational changes were disclosed.

• ·Agreement previously disclosed in 8-K filings on February 19, 2026 and March 16, 2026
• ·Common stock par value $0.001 per share
• ·Company address: 69 Wanke Boyu, Xili Liuxin 1st Rd, Nanshan District, Shenzhen, Guangdong 518052, China

30-03-2026

For the three months ended January 31, 2026, Helio Corp reported total revenue of $495,550, a sharp 65% YoY decline from $1,427,576, driven by drops in service fees (-42%), engineering fees (-91%), and materials (-92%). Operating expenses surged 129% YoY to $2,926,201, primarily from higher general and administrative costs, resulting in a net loss of $3,733,728 versus $919,142 last year. However, cash increased to $282,061 from $7,305 QoQ due to financing activities, and shareholders' deficit improved slightly to $(3,886,719).

• ·Common stock shares doubled to 23,182,425 from 11,371,966 due to issuances for services (4,262,000 shares), note conversions (7,398,459 shares), and with notes (150,000 shares).
• ·Derivative liability increased to $498,690 from $39,543 QoQ.
• ·Net cash used in operating activities improved to $(290,619) from $(501,760) YoY.
• ·Proceeds from financing: $100,000 notes payable, $559,762 convertible notes, $187,715 related party notes.

30-03-2026

PMGC Holdings Inc. reported flat revenue of 590,084 and gross profit of 185,314 for the year ended December 31, 2025, unchanged from 2024. However, total operating expenses nearly doubled to 7,067,262 from 3,663,566, driven by increases in office and administration (105%), professional fees (153%), and consulting fees (29%), while marketing and promotion declined 31%; this resulted in a widened net loss of 7,780,740 from 4,016,714. The company stated no intention to declare dividends, with returns dependent on stock appreciation, and highlighted risks in its acquisition-driven growth strategy.

• ·No intention to declare dividends on Common Stock in the foreseeable future.
• ·Other income (expense) worsened to $(867,820) from $(353,148).
• ·Weighted average shares outstanding increased from 947 to 20,352.

30-03-2026

Eikon Therapeutics reported a widened net loss of $324,248 thousand for the year ended December 31, 2025, up 33% from $243,814 thousand in 2024, driven by total operating expenses rising 30% to $338,945 thousand with R&D up 22% and G&A up 59%. While the company raised $352,053 thousand through financing activities including Series D preferred stock issuance netting $350,153 thousand, operating cash use increased 40% to $188,516 thousand and cash & equivalents fell to $104,901 thousand from $129,179 thousand. Total assets grew to $594,734 thousand supported by higher marketable securities of $231,074 thousand, though stockholders' deficit deepened to $879,034 thousand.

• ·Impairment of operating lease right-of-use assets: $10,275 thousand in 2025
• ·Impairment of property and equipment: $10,951 thousand in 2025
• ·Net loss per share basic and diluted: $(115.29) in 2025 vs $(96.76) in 2024
• ·Stock-based compensation expense: $18,036 thousand in 2025 (up from $12,429 thousand)
• ·Purchase of marketable securities: $444,102 thousand in 2025
• ·Proceeds from maturities of marketable securities: $309,500 thousand in 2025

30-03-2026

Atmos Energy Corporation extended the maturity of its $1.5 billion senior unsecured Three Year Credit Facility by one year to March 28, 2029, and its $1.5 billion senior unsecured Five Year Credit Facility by one year to March 28, 2031, both effective as of March 27, 2026. These extensions, made pursuant to Section 2.23 of each Revolving Credit Agreement originally entered on March 28, 2024, maintain the company's total revolving credit capacity at $3.0 billion without other reported changes.

• ·Extensions allow for up to two one-year extensions total per facility
• ·Facilities administered by Crédit Agricole as Administrative Agent

30-03-2026

Benchmark 2025-V19 Mortgage Trust filed its Form 10-K annual report for the fiscal year ended December 31, 2025, on March 30, 2026, including assessments of compliance with servicing criteria and servicer compliance statements from entities like Midland Loan Services and Citibank, N.A. Explanatory notes highlight that key mortgage loans—Empire Mall (6.8% of initial pool), 9911 Belward (4.1%), 1700 Pavillion (3.4%), and Central Arts Plaza (1.2%)—are parts of loan combinations serviced under separate PSAs such as WFCM 2025-5C7 and Benchmark 2025-V18. No material legal proceedings, significant obligors, or external credit enhancements are reported, with most traditional financial sections omitted as is standard for such trusts.

• ·No mortgage loan in the pool constitutes a significant obligor per Item 1101(k)(2) of Regulation AB.
• ·No external credit enhancement, derivative instruments, or other support for certificates.
• ·No unresolved staff comments, legal proceedings material to security holders, or cybersecurity disclosures required.

30-03-2026

Brookfield Real Estate Income Trust Inc. declared March 2026 distributions of $0.0721 gross per share for all classes of common stock, with net distributions ranging from $0.0522 (Class T) to $0.0721 (Class E) after deducting management and stockholder servicing fees. Distributions are payable on or about April 20, 2026 to stockholders of record as of March 30, 2026, in cash or reinvested via the distribution reinvestment plan. No period-over-period comparisons were provided.

• ·Distributions payable in cash or reinvested in shares for participants in the Company’s distribution reinvestment plan.

30-03-2026

Constellation Energy Corp filed a DEFA14A proxy supplement on March 30, 2026, disclosing that director Alan Armstrong resigned from the Board effective March 23, 2026, and is no longer a nominee for election at the Annual Meeting. All other nominees continue to stand for election, and existing proxy cards remain valid except that votes for Mr. Armstrong will be disregarded. No other agenda items in the original Proxy Statement are affected.

• ·Original Proxy Statement filed with the SEC on March 26, 2026
• ·Shareholders who have already submitted proxies do not need to take action unless they wish to change their vote

30-03-2026

Cleco Securitization I LLC filed its 10-K annual report on March 30, 2026, disclosing details on executive officers and employment history. William G. Fontenot, 63, has served as President and Chief Executive Officer of Cleco Corporate Holdings LLC since January 2018 and President and Manager of Cleco Securitization I LLC since March 2025. Samuel S. Kennedy, 41, was appointed Controller and Chief Accounting Officer since January 2026, with prior roles including Assistant Controller and positions at Vermont Gas Systems, Inc. and PricewaterhouseCoopers.

• ·Cleco Power LLC is a wholly owned subsidiary of Cleco Corporate Holdings LLC.
• ·Financial statements and schedules are not applicable per the filing.
• ·List of exhibits incorporated by reference.

30-03-2026

CVD Equipment Corporation reported Q4 2025 revenue of $5.0 million, down 33.1% YoY, gross margin of 22.1% versus 26.4%, and a net loss of $1.3 million compared to net income of $0.1 million in the prior year quarter. For FY 2025, revenue fell 4.1% to $25.8 million with improved gross margin of 28.3% versus 22.5%, narrowing the net loss to $1.6 million from $1.9 million, though cash decreased to $8.7 million from $12.6 million. The company entered a definitive agreement to sell its SDC division to Atlas Copco Group for $16.9 million in cash (net ~$15.0 million), expected to close in Q2 2026.

• ·Implemented workforce reduction expected to save $1.8M in annual operating costs starting FY 2026.
• ·SDC sale includes retention of Saugerties facility with 2-year lease to buyer.
• ·Conference call scheduled for March 30, 2026 at 5:00 PM ET.

30-03-2026

Intellinetics reported Q4 2025 total revenue of $4.3 million, up 1.0% YoY to $4,323,843 driven by 8.4% SaaS growth to $1,603,641, though professional services declined 1.8% and net loss widened to $207,975 ($0.05/share) from $53,701 ($0.01/share). For full-year 2025, total revenue fell 8.0% YoY to $16,583,446 due to an 18.7% drop in professional services despite 11.3% SaaS growth to $6,331,167, with gross profit down 3.7%, net loss expanding to $1,872,895 ($0.44/share) from $546,215 ($0.13/share), and Adjusted EBITDA declining to $469,694 from $2,382,357. Management anticipates SaaS growth in 2026 amid focus on software-led expansion.

• ·Q4 Adjusted EBITDA $260,749 vs $531,241 YoY (decline).
• ·FY gross profit margin increased 295 basis points despite volume decline.
• ·Cash balance $2,528,281 at Dec 31, 2025 (up slightly from $2,489,236).
• ·Total current liabilities decreased to $5,056,120 from $6,597,773.

30-03-2026

Cleco Securitization II LLC filed its 10-K annual report on March 30, 2026, primarily disclosing executive management details for William G. Fontenot (63, President and Manager since March 2025) and Samuel S. Kennedy (41, Controller and Chief Accounting Officer since January 2026). The filing indicates that financial statements and schedules are not applicable, with exhibits incorporated by reference. No quantitative financial performance data or period comparisons are provided.

• ·William G. Fontenot: President and CEO of Cleco Corporate Holdings LLC since January 2018; CEO of Cleco Power LLC since February 2019; President and Manager of Cleco Securitization I LLC since June 2022.
• ·Samuel S. Kennedy: Assistant Controller from May 2022 to December 2025; Controller at Vermont Gas Systems, Inc. from September 2021 to April 2022; Director at PricewaterhouseCoopers from July 2015 to September 2021.
• ·Cleco Power LLC is a wholly owned subsidiary of Cleco Corporate Holdings LLC.

30-03-2026

Deep Isolation Nuclear, Inc. reported annual revenue of $6,136 thousand for the year ended December 31, 2025, down 13% YoY from $7,053 thousand in 2024, while gross profit rose modestly 3% to $3,502 thousand amid a 28% reduction in cost of services. Operating expenses doubled to $9,272 thousand, driven by SG&A expenses surging 111% to $8,753 thousand, leading to an operating loss widening to $5,770 thousand from $1,066 thousand and net loss to $5,336 thousand from $994 thousand. However, financing activities provided $29,198 thousand, increasing cash to $27,432 thousand from $2,149 thousand.

• ·Common shares outstanding increased to 57,542,113 at Dec 31, 2025 from 39,901,782 at Dec 31, 2024 due to private placement (11,012,387 shares), stock options exercise (4,404,814 shares), and reverse acquisition adjustments.
• ·Pro forma fully diluted ownership: Deep Isolation Stockholders 63.89%, Private Placement Investors 13.23%.
• ·Net cash used in operating activities increased to $3,931 thousand from $1,201 thousand.
• ·Accounts receivable decreased to $439 thousand from $999 thousand.

30-03-2026

Hecla Mining Company filed an 8-K/A on March 30, 2026, amending its March 25, 2026 original 8-K to include unaudited pro forma condensed consolidated financial information for the years ended December 31, 2025, 2024, and 2023, and as of December 31, 2025, pursuant to Item 9.01(b). The amendment relates to the completion of the sale of its wholly-owned subsidiary, Hecla Quebec Inc., to 17629346 Canada Inc., an affiliate of Orezone Gold Corporation, on March 25, 2026. No other changes were made to the original report.

• ·Transaction initially announced on January 26, 2026, and disclosed in 8-K filed January 28, 2026.
• ·Pro forma financials attached as Exhibit 99.2.

30-03-2026

Relativity Acquisition Corp (ACQC) filed an 8-K on March 30, 2026, under Items 5.07 (Submission of Matters to a Vote of Security Holders) and 9.01 (Financial Statements and Exhibits). The report includes Exhibit 104 (Cover Page Interactive Data File) and is signed by CEO Tarek Tabsh. No specific voting results or financial details are provided in the filing content.

• ·Event date: 2026-03-25
• ·Filing date: March 30, 2026
• ·CIK: 0001860484

30-03-2026

Teladoc Health (NYSE: TDOC) appointed Susan Salka, former president and CEO of AMN Healthcare Services, to its board of directors effective March 30, 2026, following the retirements of directors Eric Evans and Thomas McKinley and the recent appointment of Michael Smith. Ms. Salka, who during her 33-year tenure at AMN drove 26 acquisitions and grew revenue to over $5 billion, will serve on the board's audit and compensation committees. Chairman Kenneth H. Paulus highlighted her healthcare leadership and governance experience to support Teladoc's care delivery transformation.

• ·Susan Salka holds an MBA in Finance from San Diego State University and a BA in Accounting and Economics from Chadron State College.
• ·Investor contact: Michael Minchak (IR@teladochealth.com, 617-444-9612).
• ·Media contact: Lou Serio (PR@teladochealth.com, 202-569-9715).

30-03-2026

Sangamo Therapeutics reported FY2025 revenues of $39,552 thousand, down 32% YoY from $57,800 thousand, contributing to a widened net loss of $122,932 thousand from $97,941 thousand. While total operating expenses edged down 1% to $160,791 thousand, driven by a 22% reduction in general and administrative expenses to $34,886 thousand, research and development expenses were nearly flat up 1% to $112,670 thousand and impairment of long-lived assets surged 140% to $13,235 thousand. Cash and cash equivalents declined to $20,948 thousand from $41,918 thousand, total assets shrank to $59,745 thousand from $101,635 thousand, and stockholders' equity flipped to a $14,268 thousand deficit from a $22,770 thousand surplus.

• ·Revenue from collaboration agreements: $37.1 million in 2025
• ·Operating lease right-of-use assets: $3,064 thousand at Dec 31 2025 (down from $16,869 thousand)
• ·Impairment details: $10.4 million on RoU assets and $2.8 million on leasehold improvements at Brisbane facility
• ·Basic and diluted net loss per share: $(0.44) in 2025 vs $(0.49) in 2024
• ·Accumulated deficit: $1,627,249 thousand at Dec 31 2025

30-03-2026

Wells Fargo Commercial Mortgage Securities, Inc. entered into an underwriting agreement dated March 26, 2026, for the sale of Publicly Offered Certificates with an aggregate initial principal amount of $510,127,000, scheduled for on or about April 21, 2026, as part of Commercial Mortgage Pass-Through Certificates, Series 2026-C66 issued by Wells Fargo Commercial Mortgage Trust 2026-C66. The issuing entity's assets will consist of 29 fixed-rate mortgage loans secured by 49 commercial and/or multifamily properties, acquired from multiple originators including Wells Fargo Bank, Societe Generale Financial Corporation, JPMorgan Chase Bank, and others. Privately Offered Certificates have an aggregate initial principal amount of $76,225,904, to be sold exempt from registration.

• ·Pooling and Servicing Agreement dated and effective as of April 1, 2026
• ·Underwriting Agreement dated March 26, 2026, with underwriters including Wells Fargo Securities, LLC, SG Americas Securities, LLC, J.P. Morgan Securities LLC, and others
• ·Mortgage loans sourced via separate purchase agreements from 10 originators dated March 26, 2026
• ·Certain whole loans governed by Intercreditor Agreements and some by Non-Serviced PSAs, including properties like NOVA Retail 2-Pack, Marriott Anchorage Downtown Hotel, and Sheraton Denver Downtown Hotel

30-03-2026

Kochav Defense Acquisition Corp., a blank check company with no operating history or revenues, outlines its strategy to target underperforming defense-related businesses for acquisition, focusing on revitalization, strong free cash flow potential, and revenue growth through operational improvements. Key risks include potential foreign asset concentration post-business combination, negative interest rates on Trust Account investments, and reliance on Working Capital Loans up to $1,500,000 from the Sponsor or affiliates. Shareholders have limited basis to evaluate success, with no current operations.

• ·Working Capital Loans may be made by Sponsor, affiliates, or certain directors/officers to finance transaction costs.
• ·Loans, if made, have undetermined terms with no written agreements existing.
• ·Post-combination units from conversion identical to Private Placement Units.

30-03-2026

Costamare Bulkers Holdings Ltd filed its 20-F Annual Report on March 30, 2026, disclosing as of March 16, 2026, an owned fleet of 31 dry bulk vessels (including one agreed to sell and one to acquire) with total capacity of 2,846,000 dwt, plus 19 chartered-in vessels with 2,229,000 dwt capacity and two Kamsarmax vessels under construction for charter-in by CBI. Key risks highlighted include potential oversupply reducing charter rates and profitability, substantial capital expenditures to maintain the fleet that may limit cash for dividends, stringent debt covenants such as a 0.75:1 liabilities-to-assets ratio and minimum cash of $30 million or 3% of bank debt, and challenges in securing favorable financing.

30-03-2026

Constellation Acquisition Corp I drew $5,000 in Extension Funds from an unsecured promissory note with Constellation Sponsor LP, depositing them into its trust account to extend the initial business combination deadline from March 29, 2026, to April 29, 2026. This marks the second of eleven permitted one-month extensions approved by the board's extension committee. The interest-free note matures upon business combination closing or repayment from non-trust funds if no deal occurs.

• ·Promissory note dated January 30, 2024
• ·Deadline previously March 29, 2026
• ·Eleven one-month extensions permitted under amended memorandum and articles

30-03-2026

BMO 2025-C13 Mortgage Trust, a commercial mortgage-backed securities issuing entity, filed its Form 10-K annual report for the fiscal year ended December 31, 2025, on March 30, 2026. The filing primarily includes servicing compliance reports, attestations, and servicer statements under Regulation AB, with most traditional 10-K sections omitted as is standard for ABS trusts. No significant obligors, material legal proceedings, external credit enhancements, or other issues were disclosed.

• ·Certain mortgage loans are part of combinations with companion loans held outside the issuing entity and serviced under cross-collateralized PSAs.
• ·No mortgage loan in the pool constitutes a significant obligor per Item 1101(k)(2) of Regulation AB.
• ·No external credit enhancement or derivative instruments support the certificates.

30-03-2026

PepGen Inc. announced topline results from the lowest dose (5 mg/kg) multiple ascending dose (MAD) cohort in the ongoing Phase 2 FREEDOM2 study, demonstrating favorable safety, splicing, and vHOT data. The company issued a press release (Exhibit 99.1) and filed a data update presentation titled 'FREEDOM2-DM1, 5 mg/kg Cohort Data Update' (Exhibit 99.2) for use in investor meetings. No unfavorable metrics or declines were reported.

• ·Filing date: March 30, 2026
• ·Dose level: 5 mg/kg (lowest dose MAD cohort)
• ·Study phase: Phase 2

30-03-2026

Translational Development Acquisition Corp., a SPAC, reported net income of $6,362,427 for the year ended December 31, 2025, compared to a net loss of $71,012 in 2024, primarily driven by $7,306,965 in dividends from the Trust Account which grew 4.19% to $181,657,311. However, general and administrative costs surged 381% to $944,538, cash balance declined 93.2% to $29,787, operating loss widened to $944,538, and shareholders' deficit worsened 16.8% to $6,542,108.

• ·Promissory note – related party increased to $200,000 as of Dec 31, 2025 from $0.
• ·Deferred underwriting fee remained unchanged at $6,037,500.
• ·Basic net income per Class A ordinary share improved to $0.29 from $(0.02).

30-03-2026

Benchmark 2025-V13 Mortgage Trust filed its 10-K annual report on March 30, 2026, featuring extensive reports (Exhibits 33 and 34) on assessments and attestations of compliance with servicing criteria for asset-backed securities from multiple servicers, trustees, custodians, and advisors. Coverage includes mortgage loans such as The Spiral, Pinnacle Hills Promenade, Renaissance New York Midtown Hotel, Queens Center, Tops & Kroger Portfolio, Woodland Mall, Colony Square, and CBM Portfolio under various PSAs and TSAs. No material non-compliance issues are indicated, with noted servicer transitions (e.g., Wells Fargo to Trimont LLC on March 1, 2025).

• ·Servicer transitions: Wells Fargo Bank to Trimont LLC on March 1, 2025 for Hudson Yards 2025-SPRL TSA, BMO 2024-5C8 PSA.
• ·Servicer change to Midland Loan Services on/after March 31, 2025 for BMO 2025-5C9 PSA (Pinnacle Hills Promenade and Renaissance New York Midtown Hotel loans).

30-03-2026

On March 30, 2026, ClearSign Technologies Corporation received a letter from The Nasdaq Stock Market LLC confirming that its common stock (CLIR) has regained compliance with Nasdaq Listing Rule 5550(a)(2), as the stock closed at or above $1.00 per share for ten consecutive business days. The minimum bid price compliance matter is now closed, resolving prior concerns.

• ·Filing pertains to Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits).
• ·Registrant details: Incorporated in Delaware, Commission File Number 001-35521, IRS EIN 26-2056298, address 8023 E. 63rd Place, Suite 101, Tulsa, Oklahoma 74133.

30-03-2026

Columbus Circle Capital Corp II (CMII), a blank check company with inception on April 3, 2025, filed its 10-K for the period ended December 31, 2025, disclosing no operating history or revenues while highlighting target sectors including healthcare (2024 U.S. expenditure of $5.0 trillion, projected 2028 EBITDA of $987 billion) and cryptocurrency (global market projected at $15.4 billion by 2032 with 13.1% CAGR). Risks noted include potential negative interest rates on Trust Account investments, post-combination foreign asset concentration, and reliance on up to $1,500,000 in convertible Working Capital Loans. Shareholder evaluation is limited due to lack of operations.

• ·Financial statements cover period from April 3, 2025 (inception) through December 31, 2025.
• ·Filing date: March 30, 2026.
• ·Working Capital Loans may be made by Initial Shareholders, affiliates, directors, or officers; convertible at $10.00 per unit.

30-03-2026

Beeline Holdings reported Q4 2025 net revenue of $2.5 million, up 127% YoY and 8.3% sequentially, with origination volume of $84.7 million up 44% YoY and improved loan economics including 31% higher average revenue per loan and 18% lower average cost per loan. The company launched the BeelineEquity platform, closed initial blockchain transactions, and ended 2025 with no corporate debt. However, total operating expenses rose 103% YoY to $10,554 thousand driven by $4,240 thousand in stock-based compensation, resulting in a net loss of $8,352 thousand (improved from $9,059 thousand prior year) and Adjusted EBITDA loss widening slightly to $3,366 thousand from $3,181 thousand.

• ·Ended 2025 with no corporate debt
• ·Loan economics improvements continuing into January 2026
• ·Conference call scheduled for March 30, 2026 at 5 p.m. ET

30-03-2026

PMV Consumer Acquisition Corp.'s total assets declined 3.6% YoY to $1,085,259 as of December 31, 2025, primarily due to a 3.3% drop in cash and cash equivalents to $1,077,142. Total liabilities rose 17.2% to $774,585, driven by higher accounts payable to related parties ($632,000 from $512,000), resulting in stockholder's equity falling 33.2% to $310,674 amid a widened accumulated deficit of $(722,253). The filing highlights ongoing risks including debt servicing constraints, competitive pressures, supply chain vulnerabilities, and potential product liabilities in consumer-related sectors.

• ·Derivative warrant liabilities remained flat at $2,980 YoY.
• ·Accrued expenses nearly flat at $139,605 (down slightly from $139,755).
• ·Prepaid expenses and other current assets declined to $8,117 from $11,989.
• ·Income taxes payable reduced to $0 from $6,300.

30-03-2026

On March 25, 2026, 4D Molecular Therapeutics, Inc. appointed Kristian Humer as Principal Accounting Officer, effective immediately, succeeding Ashoo Gupta who continues as Vice President, Finance and Controller. Mr. Humer, age 51, has served as the company's Chief Financial Officer and Principal Financial Officer since November 2025. No financial impacts or other changes were disclosed.

• ·Kristian Humer served as CFO at Foghorn Therapeutics, Inc. from April 2024 to November 2025.
• ·Kristian Humer was CFO and Chief Business Officer at Viridian Therapeutics, Inc. from July 2021 to September 2023.
• ·Kristian Humer held various roles at Citigroup Global Markets Inc. from January 2010 to July 2021, most recently Managing Director in Healthcare Investment Banking.
• ·Kristian Humer holds an MBA from Duke University’s Fuqua School of Business and a BA (Hons) in Accounting & Economics from the University of Reading.

30-03-2026

International Stem Cell Corp (ISCO) reported flat product sales of $9,100 thousand in 2025 versus $9,085 thousand in 2024 (0% YoY change), while cost of sales rose 7% to $4,033 thousand, causing gross profit to decline 5% to $5,067 thousand. General and administrative expenses remained flat at 0% change ($3,532 thousand), but net loss doubled to $(418) thousand from $(209) thousand (100% worse). Cash and cash equivalents decreased to $993 thousand from $1,230 thousand, with total assets at $4,819 thousand versus $5,173 thousand prior year.

• ·Net cash provided by operating activities $8 thousand in 2025 vs $13 thousand in 2024
• ·Related party note payable $3,340 thousand at Dec 31 2025
• ·Stock-based compensation expense $288 thousand in 2025 vs $466 thousand in 2024
• ·Domestic revenues $7,261 thousand (93% of biomedical product sales) vs International $1,241 thousand (2025)
• ·Property and equipment, net declined to $160 thousand from $257 thousand

30-03-2026

Elauwit Connection, Inc. filed an amended 10-Q with restated unaudited financials for the nine months ended September 30, 2025, reporting revenue of $15,548, up 200% YoY from $5,183, gross profit of $3,481 (up 294% YoY), and narrowed net loss of $1,938 from $2,383. For the three months ended September 30, 2025, revenue surged 153% YoY to $4,777 with gross profit up 562% to $1,417, reducing net loss to $639 from $970. However, the company remains unprofitable with operating loss of $1,462 for the nine months, stockholders' deficit widened to $(6,444) from $(4,536) at December 31, 2024, and total liabilities increased to $14,139 amid a $1,391 restatement adjustment reducing assets.

• ·Restatement reduced previously reported Q3 2025 revenue from $5,248 to $4,777 and accounts receivable from $4,564 to $3,173.
• ·Net cash used in operating activities improved to $1,308 from $3,114 YoY for nine months.
• ·Proceeds from SAFE liability issuance: $1,000 during nine months ended Sep 30, 2025.
• ·Cash balance increased to $762 from $287 at Dec 31, 2024.